{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T01:33:36Z","timestamp":1785202416361,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1DP1DA034787-01"],"award-info":[{"award-number":["1DP1DA034787-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003896","name":"Henry M. Jackson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000182","name":"Medical Research and Materiel Command","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jconrel.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T06:44:50Z","timestamp":1518158690000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex"],"prefix":"10.1016","volume":"275","author":[{"given":"Zoltan","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar B.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Lanar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1913-3909","authenticated-orcid":false,"given":"Carl R.","family":"Alving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2018.02.006_bb0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.it.2015.12.003","article-title":"Integration of innate immune signaling","volume":"37","author":"Thaiss","year":"2016","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2018.02.006_bb0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.02.006_bb0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jconrel.2014.06.027","article-title":"Designing and building the next generation of improved vaccine adjuvants","volume":"190","author":"Brito","year":"2014","journal-title":"J. Control. Release"},{"issue":"16","key":"10.1016\/j.jconrel.2018.02.006_bb0020","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1074\/jbc.M110.186338","article-title":"Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases","volume":"286","author":"Hickman","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2018.02.006_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.addr.2004.09.008","article-title":"Immunity in response to particulate antigen-delivery systems","volume":"57","author":"Storni","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2018.02.006_bb0030","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1073\/pnas.0804897106","article-title":"Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome","volume":"106","author":"Sharp","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.jconrel.2018.02.006_bb0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14760584.6.5.685","article-title":"Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation","volume":"6","author":"Hem","year":"2007","journal-title":"Expert Rev. Vaccines"},{"issue":"2","key":"10.1016\/j.jconrel.2018.02.006_bb0040","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jps.22284","article-title":"Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability","volume":"100","author":"Clapp","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.jconrel.2018.02.006_bb0045","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.2217\/nnm.14.193","article-title":"The impact of size on particulate vaccine adjuvants","volume":"9","author":"Shah","year":"2014","journal-title":"Nanomedicine (London)"},{"issue":"Suppl. 3","key":"10.1016\/j.jconrel.2018.02.006_bb0050","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0264-410X(02)00166-4","article-title":"Aluminum salts in vaccines\u2014US perspective","volume":"20","author":"Baylor","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.02.006_bb0055","author":"Working in Tandem, Ltd., for the PATH Vaccine and Pharmaceutical Technologies Group"},{"key":"10.1016\/j.jconrel.2018.02.006_bb0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fimmu.2012.00406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"HogenEsch","year":"2013","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.jconrel.2018.02.006_bb0065","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00003495-200363100-00006","article-title":"Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.jconrel.2018.02.006_bb0070","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1016\/j.vaccine.2007.01.013","article-title":"Developing an HPV vaccine to prevent cervical cancer and genital warts","volume":"25","author":"Bryan","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jconrel.2018.02.006_bb0075","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev. Vaccines"},{"issue":"2","key":"10.1016\/j.jconrel.2018.02.006_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev. Vaccines"},{"issue":"10","key":"10.1016\/j.jconrel.2018.02.006_bb0085","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"issue":"20","key":"10.1016\/j.jconrel.2018.02.006_bb0090","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0264-410X(99)00566-6","article-title":"A hepatitis B vaccine formulated with a novel adjuvant system","volume":"18","author":"Ambrosch","year":"2000","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.jconrel.2018.02.006_bb0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18\u201345\u202fyears","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccin."},{"issue":"8","key":"10.1016\/j.jconrel.2018.02.006_bb0100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jit657","article-title":"Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial","volume":"209","author":"Toft","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2018.02.006_bb0105","first-page":"1","article-title":"Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females","author":"Haskins-Coulter","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.jconrel.2018.02.006_bb0110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1073\/pnas.89.1.358","article-title":"Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy","volume":"89","author":"Fries","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.jconrel.2018.02.006_bb0115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/erv.12.35","article-title":"Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines","volume":"11","author":"Alving","year":"2012","journal-title":"Expert Rev. Vaccines"},{"issue":"3","key":"10.1016\/j.jconrel.2018.02.006_bb0120","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbamem.2014.12.005","article-title":"Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate","volume":"1848","author":"Beck","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"42","key":"10.1016\/j.jconrel.2018.02.006_bb0125","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1016\/j.vaccine.2015.09.001","article-title":"Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21","volume":"33","author":"Beck","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jconrel.2018.02.006_bb0130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/17425247.2016.1151871","article-title":"Adjuvants for human vaccines","volume":"13","author":"Alving","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2018.02.006_bb0135","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/acs.bioconjchem.5b00085","article-title":"Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers","volume":"26","author":"Jalah","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"13","key":"10.1016\/j.jconrel.2018.02.006_bb0140","article-title":"Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant","volume":"2","author":"Torres","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2018.02.006_bb0145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0076-6879(03)73003-1","article-title":"Oil-in-water liposomal emulsions for vaccine delivery","volume":"373","author":"Matyas","year":"2003","journal-title":"Methods Enzymol."},{"issue":"3","key":"10.1016\/j.jconrel.2018.02.006_bb0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.it.2009.12.009","article-title":"The immunobiology of aluminium adjuvants: how do they really work?","volume":"31","author":"Exley","year":"2010","journal-title":"Trends Immunol."},{"issue":"41","key":"10.1016\/j.jconrel.2018.02.006_bb0155","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1016\/j.vaccine.2017.02.040","article-title":"Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants","volume":"35","author":"Seth","year":"2017","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.jconrel.2018.02.006_bb0160","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1016\/j.vaccine.2017.05.070","article-title":"Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013","volume":"35","author":"Genito","year":"2017","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jconrel.2018.02.006_bb0165","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/1044-579X(95)90007-1","article-title":"Selection of potent immunological adjuvants for vaccine construction","volume":"6","author":"McElrath","year":"1995","journal-title":"Semin. Cancer Biol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591830066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591830066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:34:20Z","timestamp":1759160060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591830066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":33,"alternative-id":["S016836591830066X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.02.006","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}